Bert Bruce, MBA is Vice President for Rare Disease Commercial Development at Pfizer, Inc. His responsibilities span drug development, business development, commercial preparedness and lifecycle management for development and commercialized Rare Disease medicines. He is also accountable for the development and execution of enterprise strategies in Rare Disease. Bert has a diverse skill set and broad pharmaceutical background, with leadership experiences across multiple therapeutics areas and disciplines and Johnson & Johnson, Wyeth and Pfizer. He has been an integral leader in complex programs including the Alzheimer’s Immunotherapy Program and the acquisition team that brought tafamidis (Vyndaqel®) into the Pfizer Rare Disease Portfolio.
Bert earned a B.S. from Eastern College and an M.B.A. from the University of Pennsylvania’s Wharton School of Business. He is well recognized for his strategic vision, collaborative leadership, influencing skills, and development of high-performing teams; his professional passions include improving the participation of minorities in clinical trials and leadership development. Bert currently serves as an Executive Council Member of the National Biotechnology and Pharmaceutical Association, an Executive Board Member of the Get Together Group, a professional life-science networking organization, and as a member of the Pfizer Global Blacks Council.